Published in Lancet on June 28, 2011
Intravenous CTLA4-lg Treatment in Recent Onset Type 1 Diabetes Mellitus | NCT00505375
Detection of C-peptide in Youth With Longstanding Type 1 Diabetes Mellitus | NCT02131675
Standards of medical care in diabetes--2013. Diabetes Care (2013) 24.85
Type 1 diabetes. Lancet (2013) 3.45
Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet (2011) 3.13
Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes (2012) 3.11
Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet (2013) 2.45
Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol (2013) 2.23
Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. Diabetes (2012) 2.02
Blood and islet phenotypes indicate immunological heterogeneity in type 1 diabetes. Diabetes (2014) 1.89
A plasmonic chip for biomarker discovery and diagnosis of type 1 diabetes. Nat Med (2014) 1.72
Circulating microRNAs as novel biomarkers for diabetes mellitus. Nat Rev Endocrinol (2013) 1.69
Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nat Rev Immunol (2013) 1.65
B7 family checkpoint regulators in immune regulation and disease. Trends Immunol (2013) 1.53
Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: evidence of improved immune regulation. Diabetes (2011) 1.52
Reversal of type 1 diabetes via islet β cell regeneration following immune modulation by cord blood-derived multipotent stem cells. BMC Med (2012) 1.44
Immune therapy and β-cell death in type 1 diabetes. Diabetes (2013) 1.33
Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics. Crit Rev Biotechnol (2013) 1.31
β cell death and dysfunction during type 1 diabetes development in at-risk individuals. J Clin Invest (2015) 1.31
Recent lessons learned from prevention and recent-onset type 1 diabetes immunotherapy trials. Diabetes (2013) 1.30
Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia (2012) 1.29
B-lymphocyte depletion with rituximab and β-cell function: two-year results. Diabetes Care (2013) 1.25
Current concepts on the pathogenesis of type 1 diabetes--considerations for attempts to prevent and reverse the disease. Diabetes Care (2015) 1.25
Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment. Diabetes Care (2013) 1.21
Year in diabetes 2012: The diabetes tsunami. J Clin Endocrinol Metab (2012) 1.19
Treating human autoimmunity: current practice and future prospects. Sci Transl Med (2012) 1.16
Targeting co-stimulatory pathways: transplantation and autoimmunity. Nat Rev Nephrol (2013) 1.11
Through the fog: recent clinical trials to preserve β-cell function in type 1 diabetes. Diabetes (2012) 1.07
Progress in immune-based therapies for type 1 diabetes. Clin Exp Immunol (2013) 1.06
The application of the diabetes prevention trial-type 1 risk score for identifying a preclinical state of type 1 diabetes. Diabetes Care (2012) 1.03
Can existing drugs approved for other indications retard renal function decline in patients with type 1 diabetes and nephropathy? Semin Nephrol (2012) 1.02
Immune therapy in type 1 diabetes mellitus. Nat Rev Endocrinol (2013) 1.02
Rationale and study design of the Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D): a non-randomised, open label, adaptive dose finding trial. BMJ Open (2014) 1.01
Breakdown in peripheral tolerance in type 1 diabetes in mice and humans. Cold Spring Harb Perspect Med (2012) 1.00
Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol (2014) 0.97
Transient B-cell depletion with anti-CD20 in combination with proinsulin DNA vaccine or oral insulin: immunologic effects and efficacy in NOD mice. PLoS One (2013) 0.97
Clinical implications of shared genetics and pathogenesis in autoimmune diseases. Nat Rev Endocrinol (2013) 0.96
The IL-2/IL-2R system: from basic science to therapeutic applications to enhance immune regulation. Immunol Res (2013) 0.94
The problems and promises of research into human immunology and autoimmune disease. Nat Med (2012) 0.94
CD28 and ITK signals regulate autoreactive T cell trafficking. Nat Med (2013) 0.93
Restoring the balance: immunotherapeutic combinations for autoimmune disease. Dis Model Mech (2014) 0.92
Targeting regulatory T cells in the treatment of type 1 diabetes mellitus. Curr Mol Med (2012) 0.92
Current and future immunomodulation strategies to restore tolerance in autoimmune diseases. Cold Spring Harb Perspect Biol (2012) 0.91
Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report. Diabetes Care (2015) 0.91
CD28 Costimulation: From Mechanism to Therapy. Immunity (2016) 0.90
Investigation of soluble and transmembrane CTLA-4 isoforms in serum and microvesicles. J Immunol (2014) 0.89
Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial. PLoS Med (2016) 0.89
From immunobiology to β-cell biology: the changing perspective on type 1 diabetes. Islets (2014) 0.88
Thinking bedside at the bench: the NOD mouse model of T1DM. Nat Rev Endocrinol (2015) 0.88
Screening for insulinoma antigen 2 and zinc transporter 8 autoantibodies: a cost-effective and age-independent strategy to identify rapid progressors to clinical onset among relatives of type 1 diabetic patients. Clin Exp Immunol (2013) 0.88
Reduction in CD4 central memory T-cell subset in costimulation modulator abatacept-treated patients with recent-onset type 1 diabetes is associated with slower C-peptide decline. Diabetes (2014) 0.87
Functional characterization of human T cell hyporesponsiveness induced by CTLA4-Ig. PLoS One (2015) 0.85
The Role of Dendritic Cell Subsets and Innate Immunity in the Pathogenesis of Type 1 Diabetes and Other Autoimmune Diseases. Front Immunol (2015) 0.85
Clinical immunologic interventions for the treatment of type 1 diabetes. Cold Spring Harb Perspect Med (2012) 0.85
β-cell-specific CD8 T cell phenotype in type 1 diabetes reflects chronic autoantigen exposure. Diabetes (2014) 0.84
Anti-cytokine therapies in T1D: Concepts and strategies. Clin Immunol (2013) 0.84
Mechanistic basis of immunotherapies for type 1 diabetes mellitus. Transl Res (2013) 0.84
HLA-A*24 is an independent predictor of 5-year progression to diabetes in autoantibody-positive first-degree relatives of type 1 diabetic patients. Diabetes (2012) 0.84
New and future immunomodulatory therapy in type 1 diabetes. Trends Mol Med (2012) 0.83
ICOS is required for the generation of both central and effector CD4(+) memory T-cell populations following acute bacterial infection. Eur J Immunol (2015) 0.82
Dead or alive? Diabetes Care (2012) 0.82
Heterogeneity in recent-onset type 1 diabetes - a clinical trial perspective. Diabetes Metab Res Rev (2015) 0.81
Life and death of β cells in Type 1 diabetes: A comprehensive review. J Autoimmun (2016) 0.81
Diabetes: type 1 diabetes mellitus--a door opening to a real therapy? Nat Rev Endocrinol (2011) 0.81
Can we vaccinate against Type 1 diabetes? F1000 Biol Rep (2012) 0.81
Variation in the CTLA4 3'UTR has phenotypic consequences for autoreactive T cells and associates with genetic risk for type 1 diabetes. Genes Immun (2015) 0.81
Costimulation Blockade in Autoimmunity and Transplantation: The CD28 Pathway. J Immunol (2016) 0.80
Targeting dendritic cell function during systemic autoimmunity to restore tolerance. Int J Mol Sci (2014) 0.80
Type 1 diabetes mellitus in 2011: Heterogeneity of T1DM raises questions for therapy. Nat Rev Endocrinol (2011) 0.80
Type 1 diabetes: A predictable disease. World J Diabetes (2015) 0.80
Targeting the trimolecular complex. Clin Immunol (2013) 0.80
Biomarkers in type 1 diabetes: application to the clinical trial setting. Curr Opin Endocrinol Diabetes Obes (2014) 0.80
Immune interventions to preserve β cell function in type 1 diabetes. J Investig Med (2016) 0.80
Inhibition of Phosphoinositide 3-Kinase p110delta Does Not Affect T Cell Driven Development of Type 1 Diabetes Despite Significant Effects on Cytokine Production. PLoS One (2016) 0.79
Immune-directed therapy for type 1 diabetes at the clinical level: the Immune Tolerance Network (ITN) experience. Rev Diabet Stud (2012) 0.79
Prevention of type 1A diabetes mellitus. Endocr Pract (2012) 0.79
TIM4 Regulates the Anti-Islet Th2 Alloimmune Response. Cell Transplant (2014) 0.79
The role of the innate immune system in destruction of pancreatic beta cells in NOD mice and humans with type I diabetes. J Autoimmun (2016) 0.78
Obstacles and opportunities for targeting the effector T cell response in type 1 diabetes. J Autoimmun (2016) 0.78
Non-antigenic and antigenic interventions in type 1 diabetes. Hum Vaccin Immunother (2013) 0.78
Prospects for therapeutic tolerance in humans. Curr Opin Rheumatol (2014) 0.78
Nucleic acid biomarkers of β cell stress and death in type 1 diabetes. Curr Opin Endocrinol Diabetes Obes (2016) 0.78
Mechanistic evidence in support of alpha1-antitrypsin as a therapeutic approach for type 1 diabetes. J Diabetes Sci Technol (2014) 0.78
Cellular and humoral immune responses in type 1 diabetic patients participating in a phase III GAD-alum intervention trial. Diabetes Care (2013) 0.78
Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy. Immunol Rev (2017) 0.78
Biomarkers of β-Cell Stress and Death in Type 1 Diabetes. Curr Diab Rep (2016) 0.77
Altering the course of type 1 diabetes: an update on prevention and new-onset clinical trials. Pediatr Diabetes (2013) 0.77
Commensal microbes drive intestinal inflammation by IL-17-producing CD4+ T cells through ICOSL and OX40L costimulation in the absence of B7-1 and B7-2. Proc Natl Acad Sci U S A (2014) 0.77
Targeted immune interventions for type 1 diabetes: not as easy as it looks! Curr Opin Endocrinol Diabetes Obes (2014) 0.77
Perspective: Rethink the immune connection. Nature (2012) 0.77
Dead on arrival: understanding the failure of CTLA4-immunoglobulin therapy in inflammatory bowel disease. Gastroenterology (2012) 0.77
Staging the progression to type 1 diabetes with prediagnostic markers. Curr Opin Endocrinol Diabetes Obes (2016) 0.77
Immunomodulators: Cell savers. Nature (2012) 0.77
New hope for immune intervention therapy in type 1 diabetes. Lancet (2011) 0.77
The compelling case for anti-CD3 in type 1 diabetes. Diabetes (2013) 0.77
Immunotherapy trials for type 1 diabetes: the contribution of George Eisenbarth. Diabetes Technol Ther (2013) 0.76
Antigen-based vs. systemic immunomodulation in type 1 diabetes: the pros and cons. Islets (2013) 0.76
Trials in the prevention of type 1 diabetes: current and future. Can J Diabetes (2014) 0.76
Clinical potential of antigen-specific therapies in type 1 diabetes. Rev Diabet Stud (2012) 0.76
Immunotherapy in autoimmune type 1 diabetes. Rev Diabet Stud (2012) 0.76
Fall in C-Peptide During First 4 Years From Diagnosis of Type 1 Diabetes: Variable Relation to Age, HbA1c, and Insulin Dose. Diabetes Care (2016) 0.76
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med (1993) 102.56
Standards of medical care in diabetes--2011. Diabetes Care (2011) 21.94
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med (2005) 10.16
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med (2002) 8.84
Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med (2009) 6.89
Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group. Ann Intern Med (1998) 6.13
GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med (2008) 5.74
Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care (2003) 4.92
Costimulation blockade with belatacept in renal transplantation. N Engl J Med (2005) 4.86
C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes (2004) 4.44
Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med (1995) 3.18
Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet (2008) 3.00
Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care (2008) 2.87
Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia (2010) 2.65
CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest (1999) 2.58
Selective targeting of human alloresponsive CD8+ effector memory T cells based on CD2 expression. Am J Transplant (2010) 2.37
Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum (2011) 2.11
Type 1 diabetes as a relapsing-remitting disease? Nat Rev Immunol (2007) 2.04
Immunotherapy of type 1 diabetes: where are we and where should we be going? Immunity (2010) 1.98
Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial. Ann Rheum Dis (2007) 1.86
Stopping type 1 diabetes: attempts to prevent or cure type 1 diabetes in man. Diabetes (2011) 1.77
CTLA4Ig: bridging the basic immunology with clinical application. Immunity (2006) 1.75
A two-signal model for T cell trafficking. Trends Immunol (2007) 1.13
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med (2005) 27.77
Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med (2008) 17.19
CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med (2006) 14.33
Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science (2008) 14.26
Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med (2006) 13.63
Promoting coherent minimum reporting guidelines for biological and biomedical investigations: the MIBBI project. Nat Biotechnol (2008) 12.96
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A (2005) 10.89
Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol (2009) 9.67
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med (2002) 8.84
Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med (2011) 8.54
Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med (2009) 6.89
Pedophilia, hebephilia, and the DSM-V. Arch Sex Behav (2008) 6.78
Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med (2011) 6.74
BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer (2005) 5.57
Autoimmune polyendocrine syndromes. N Engl J Med (2004) 5.11
Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1. Diabetes Care (2005) 5.04
The effect of continuous glucose monitoring in well-controlled type 1 diabetes. Diabetes Care (2009) 4.93
Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care (2009) 4.79
Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 4.78
Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care (2003) 4.50
C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes (2004) 4.44
Human oocytes reprogram somatic cells to a pluripotent state. Nature (2011) 4.03
Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care (2013) 3.89
Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation (2007) 3.88
Nephrogenic syndrome of inappropriate antidiuresis. N Engl J Med (2005) 3.83
Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial. Arch Intern Med (2007) 3.58
Usability in the real world: assessing medical information technologies in patients' homes. J Biomed Inform (2003) 3.45
Generation of pluripotent stem cells from patients with type 1 diabetes. Proc Natl Acad Sci U S A (2009) 3.43
Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol (2009) 3.30
Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA (2004) 3.20
Free radical-induced damage to DNA: mechanisms and measurement. Free Radic Biol Med (2002) 3.18
Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet (2011) 3.13
Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes (2012) 3.11
Repeatability and reproducibility in proteomic identifications by liquid chromatography-tandem mass spectrometry. J Proteome Res (2010) 3.08
Columbia University's Informatics for Diabetes Education and Telemedicine (IDEATel) Project: rationale and design. J Am Med Inform Assoc (2001) 3.06
Tumor necrosis factor-alpha converting enzyme (TACE) regulates epidermal growth factor receptor ligand availability. J Biol Chem (2002) 3.03
Toward defining the autoimmune microbiome for type 1 diabetes. ISME J (2010) 3.03
A randomized trial comparing telemedicine case management with usual care in older, ethnically diverse, medically underserved patients with diabetes mellitus. J Am Med Inform Assoc (2005) 3.01
The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes (2006) 3.00
Response to nocturnal alarms using a real-time glucose sensor. Diabetes Technol Ther (2005) 2.98
Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care (2009) 2.91
A randomized trial comparing telemedicine case management with usual care in older, ethnically diverse, medically underserved patients with diabetes mellitus: 5 year results of the IDEATel study. J Am Med Inform Assoc (2009) 2.90
Cross-sectional multicenter study of patients with urea cycle disorders in the United States. Mol Genet Metab (2008) 2.90
Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the Ambulatory Glucose Profile (AGP). Diabetes Technol Ther (2013) 2.85
Granulocyte/macrophage-colony-stimulating factor autoantibodies and myeloid cell immune functions in healthy subjects. Blood (2009) 2.79
Most youth with type 1 diabetes in the T1D Exchange Clinic Registry do not meet American Diabetes Association or International Society for Pediatric and Adolescent Diabetes clinical guidelines. Diabetes Care (2013) 2.73
Harmonization of glutamic acid decarboxylase and islet antigen-2 autoantibody assays for national institute of diabetes and digestive and kidney diseases consortia. J Clin Endocrinol Metab (2010) 2.70
A risk score for type 1 diabetes derived from autoantibody-positive participants in the diabetes prevention trial-type 1. Diabetes Care (2007) 2.67
Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation (2008) 2.65
Comparison of fingerstick hemoglobin A1c levels assayed by DCA 2000 with the DCCT/EDIC central laboratory assay: results of a Diabetes Research in Children Network (DirecNet) Study. Pediatr Diabetes (2005) 2.64
The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results. Pediatr Diabetes (2008) 2.60
Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetes. Diabetes Care (2010) 2.57
Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet (2013) 2.45